Adjuvant histamine in cancer immunotherapy

Interleukin-2 (IL-2) is an effective activator of lymphocytes with anti-neo plastic properties such as T-cells or natural killer cells, and this proper ly of IL-2 has formed the basis for ifs widespread used as an immunotherape utic ag-Plzt in human neoplastic disease. In recent gears, IL-2 therapy for solid neoplastic diseases and hematopoietic cancers has been supplemented with histamine dihydrochloride with the aim of counteracting immunosuppress ive signals from monocytes/macrophages. Here we review the preclinical basi s for the use of histamine as an adjunct to IL-2 in cancer immunotherapy.